Sep 08, 2022 / NTS GMT
Kerry Stevenson - Small Caps - Moderator
Welcome to Small Caps, ladies and gentlemen. My name is Kerry Stevenson. Today I'm speaking with Steven Yatomi-Clarke. He is the Managing Director and CEO of Prescient Therapeutics, which is a really interesting company. The ASX code is PTX. They have four blue chip oncology assets, and you'll see them behind Steven's head at the movement, which makes it really easy PTX-100, PTX- 200, OmniCAR and CellPryme. So thanks for making my job easy Stephen, and welcome back to Small Caps.
Steven Yatomi-Clarke - Prescient Therapeutics Limited - CEO & MD
Thank you so much, Kerry. Delight to be speaking with you again.
Questions and Answers:
Kerry Stevenson - Small Caps - ModeratorWell, it's been a year, Stephen. So let's start because I can't believe it's let's not leave it that long next time because there's been a lot of development with Prescient. So first up, can you give us a brief overview of those four assets that you have got?
Steven Yatomi